Back to top

Guggenheim Sticks to Their Hold Rating for Arcturus Therapeutics (ARCT)

Guggenheim analyst Seamus Fernandez maintained a Hold rating on Arcturus Therapeutics yesterday. The company’s shares closed yesterday at $6.08. Ac...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Arcturus Therapeutics Holdings Inc. (ARCT)